Bodisen Biotech Inc Statement re Cancellation of Admission to Trading (6572A)
24 Dicembre 2014 - 8:00AM
UK Regulatory
TIDMBODI
RNS Number : 6572A
Bodisen Biotech Inc
24 December 2014
24 December 2014
Bodisen Biotech, Inc.
("Bodisen" or the "Company")
Cancellation of Admission to Trading on AIM
Bodisen announced on 24 June 2014 that the Company had been
unable to publish its audited results for the year ended 31
December 2013 and accordingly, the Company's ordinary shares were
suspended from trading on AIM.
The Company remains unable to confirm when the audit for the
year to 31 December 2013 will be completed or when the accounts
will be published.
As a result, and in accordance with AIM Rule 41, admission of
the Company's shares to trading AIM will be cancelled on 29
December 2014 at which point the Company's shares will have been
suspended from trading for six months.
Bodisen shares continue to be traded on the OTC market in the
United States (ticker: BBCZ).
Charles Stanley Securities confirms that it will resign as the
Company's Nominated Adviser and Broker with effect from 29 December
2014.
Enquiries:
Bodisen Biotech, Inc.
Lin Wang 0086 29 8707 4957
Charles Stanley Securities
(Nominated Adviser)
Russell Cook / Carl Holmes 020 7149 6000
This information is provided by RNS
The company news service from the London Stock Exchange
END
STRPGGMPPUPCGMW
Grafico Azioni Bodisen Biotech (LSE:BODI)
Storico
Da Mag 2024 a Giu 2024
Grafico Azioni Bodisen Biotech (LSE:BODI)
Storico
Da Giu 2023 a Giu 2024
Notizie in Tempo Reale relative a Bodisen (Borsa di Londra): 0 articoli recenti
Più Bodisen Biotech Articoli Notizie